Welcome to LookChem.com Sign In|Join Free
  • or
1-(4-(4-bromophenyl)thiazol-2-yl)-N-(4-phenylbutyl)piperidine-4-carboxamide trifluoroacetate is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1331744-98-9

Post Buying Request

1331744-98-9 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1331744-98-9 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1331744-98-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,3,1,7,4 and 4 respectively; the second part has 2 digits, 9 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1331744-98:
(9*1)+(8*3)+(7*3)+(6*1)+(5*7)+(4*4)+(3*4)+(2*9)+(1*8)=149
149 % 10 = 9
So 1331744-98-9 is a valid CAS Registry Number.

1331744-98-9Downstream Products

1331744-98-9Relevant academic research and scientific papers

Discovery, synthesis, and biological evaluation of novel SMN protein modulators

Xiao, Jingbo,Marugan, Juan J.,Zheng, Wei,Titus, Steve,Southall, Noel,Cherry, Jonathan J.,Evans, Matthew,Androphy, Elliot J.,Austin, Christopher P.

, p. 6215 - 6233 (2011/11/06)

Spinal muscular atrophy (SMA) is an autosomal recessive disorder affecting the expression or function of survival motor neuron protein (SMN) due to the homozygous deletion or rare point mutations in the survival motor neuron gene 1 (SMN1). The human genome includes a second nearly identical gene called SMN2 that is retained in SMA. SMN2 transcripts undergo alternative splicing with reduced levels of SMN. Up-regulation of SMN2 expression, modification of its splicing, or inhibition of proteolysis of the truncated protein derived from SMN2 have been discussed as potential therapeutic strategies for SMA. In this manuscript, we detail the discovery of a series of arylpiperidines as novel modulators of SMN protein. Systematic hit-to-lead efforts significantly improved potency and efficacy of the series in the primary and orthogonal assays. Structure-property relationships including microsomal stability, cell permeability, and in vivo pharmacokinetics (PK) studies were also investigated. We anticipate that a lead candidate chosen from this series may serve as a useful probe for exploring the therapeutic benefits of SMN protein up-regulation in SMA animal models and a starting point for clinical development.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1331744-98-9